AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38856026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg and 300 mg)
Number of subjects: 230
Study 38856026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 38856026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion arms
Number of subjects: 230
Study 38856101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) and rituximab (RTX) maintenance (R2) after bendamustine and rituximab induction (BR)
Number of subjects: 36
Study 38856101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) and rituximab (RTX) maintenance (R2)
Number of subjects: 36
Study 38856101 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine and rituximab induction (BR)
Number of subjects: 36
Study 38856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus daratumumab and dexamethasone (IDd)
Number of subjects: 61
Study 38856224 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tirzepatide
Number of subjects: 190
Study 38856224 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tirzepatide
Number of subjects: 190
Study 38856224 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg tirzepatide
Number of subjects: 190
Study 38856224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 38856631 — intervention group
Group type: COMPARATOR
Intervention: ECMO duration of 0-3 days
Number of subjects: 2021
Study 38856631 — intervention group
Group type: COMPARATOR
Intervention: ECMO duration of 4-7 days
Number of subjects: 2021
Study 38856631 — intervention group
Group type: COMPARATOR
Intervention: ECMO duration of 8-10 days
Number of subjects: 2021
Study 38856631 — intervention group
Group type: COMPARATOR
Intervention: ECMO duration of greater than 10 days
Number of subjects: 2021
Study 38856631 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO duration greater than 7 days
Number of subjects: 2021
Study 38856631 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge survival
Number of subjects: 2021
Study 38856678 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab 15 mg/kg every 4 weeks with stable lipid-lowering therapy
Number of subjects: 116
Study 38856863 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 3375968 (anti-human CCR8 antibody)
Number of subjects: 0
Study 38856863 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 3375968 (anti-human CCR8 antibody) in combination with immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study 38856885 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatment planning process focused on shared decision-making (SDM)
Number of subjects: 109
Study 38856885 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment planning process
Number of subjects: 109
Study 38856885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist engagement with patient-reported data
Number of subjects: 109
Study 38856950 — intervention group
Group type: EXPERIMENTAL
Intervention: High muscular fitness (HMF)
Number of subjects: 59
Study 38856950 — intervention group
Group type: EXPERIMENTAL
Intervention: High isometric strength (HIS)
Number of subjects: 59
Study 38856950 — intervention group
Group type: EXPERIMENTAL
Intervention: High countermovement jump (HCMJ)
Number of subjects: 59
Study 38856950 — intervention group
Group type: COMPARATOR
Intervention: Low isometric and low dynamic force values (LMF)
Number of subjects: 59
Study 38856994 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 260
Study 38856994 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 260
Study 38857015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive antipyretic therapy (acetaminophen 30 mg/kg load, then 15 mg/kg plus ibuprofen 10 mg/kg every 6 hours for 72 hours)
Number of subjects: 256
Study 38857015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive antipyretic therapy
Number of subjects: 256
Study 38857015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (15 mg/kg of acetaminophen as needed every 6 hours for temperature of 38.5 °C or higher)
Number of subjects: 256
Study 38857015 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 38857019 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia
Number of subjects: 1140
Study 38857019 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1140
Study 38857209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient warning
Number of subjects: 8004
Study 38857209 — intervention group
Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 8004
Study 38857209 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 8004
Study 38857209 — intervention group
Group type: COMPARATOR
Intervention: GDA label
Number of subjects: 8004
Study 38857379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 38857379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38857463 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amivantamab-lazertinib
Number of subjects: 418
Study 38857463 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amivantamab-lazertinib
Number of subjects: 418
Study 38857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure (core temperature increase of 1.5 °C)
Number of subjects: 61
Study 38857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized opioid-prescription protocol (IOPP) with shared decision making
Number of subjects: 5521
Study 38857509 — intervention group
Group type: COMPARATOR
Intervention: Fixed quantity (20 tablets of 5 mg oxycodone)
Number of subjects: 5521
Study 38857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg orally per day) plus usual care
Number of subjects: 3144
Study 38857611 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3144
Study 38857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg orally per day)
Number of subjects: 3144
Study 38857688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise escalating energy algorithm (RaA, 150 J, 360 J, and 360 J)
Number of subjects: 300
Study 38857688 — intervention group
Group type: COMPARATOR
Intervention: Maximum fixed energy algorithm (MfA, 3 x 360 J)
Number of subjects: 300
Study 38857688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise escalating energy algorithm (RaA)
Number of subjects: 300
Study 38857688 — intervention group
Group type: COMPARATOR
Intervention: Maximum fixed energy algorithm (MfA)
Number of subjects: 300
Study 38857688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 300
Study 38857788 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 0.3 mg (single subcutaneous dose)
Number of subjects: 41
Study 38857811 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality + Pulmonary rehabilitation (VR + PR)
Number of subjects: 50
Study 38857811 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pulmonary rehabilitation (PR)
Number of subjects: 50
Study 38857913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA analysis
Number of subjects: 30
Study 38857913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescence experiments
Number of subjects: 30
Study 38857913 — intervention group
Group type: EXPERIMENTAL
Intervention: Publicly available transcriptomics data sets
Number of subjects: 30
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MACS model
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MACS estimate <0.05
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score <4
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE score <109
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of T-MACS estimates and CTCA findings
Number of subjects: 699
Study 38857986 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MACS estimate <0.05 and normal coronary arteries
Number of subjects: 699
Study 38858103 — intervention group
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine-gynx 6 mg/kg IV every 3 weeks until progression or unacceptable toxicity
Number of subjects: 105
Study 38858103 — intervention group
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine-gynx
Number of subjects: 105
Study 38858106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab plus atezolizumab (tiragolumab 600 mg + atezolizumab 1200 mg every 3 weeks)
Number of subjects: 171
Study 38858106 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab alone (1200 mg every 3 weeks)
Number of subjects: 171
Study 38858139 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-month household-based counselling intervention
Number of subjects: 16301
Study 38858145 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescriptions (≥3 SABA canisters/year)
Number of subjects: 205
Study 38858145 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA in addition to maintenance therapy
Number of subjects: 205
Study 38858145 — intervention group
Group type: COMPARATOR
Intervention: SABA canisters (≥3 vs 0-2 canisters)
Number of subjects: 205
Study 38858147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 516
Study 38858147 — intervention group
Group type: COMPARATOR
Intervention: Control (standard antiplatelet therapy)
Number of subjects: 516
Study 38858151 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor FMT (from two different donors)
Number of subjects: 80
Study 38858151 — intervention group
Group type: COMPARATOR
Intervention: Autologous FMT (placebo)
Number of subjects: 80
Study 38858157 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 100
Study 38858157 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 38858161 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoarterial ECMO treatment
Number of subjects: 64
Study 38858375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile game therapy intervention for ADHD, 4-week home-based game intervention.
Number of subjects: 110
Study 38858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise (moderate-intensity) during pregnancy
Number of subjects: 0
Study 38858465 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 0
Study 38858523 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 1 mg
Number of subjects: 98
Study 38858523 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg
Number of subjects: 98
Study 38858523 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg
Number of subjects: 98
Study 38858523 — intervention group
Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg
Number of subjects: 98
Study 38858523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 38858569 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA delivery
Number of subjects: 0
Study 38858629 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as Usual + Mindfulness (TaU + MIND)
Number of subjects: 177
Study 38858629 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 177
Study 38858721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment peripheral blood myeloid cells in TNBC
Number of subjects: 126
Study 38858721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment CD8+ naive T cells and CD4+ effector memory cells re-expressing CD45RA in hormone receptor-positive breast cancer
Number of subjects: 126
Study 38858743 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental psychoeducational intervention targeting insomnia (B2)
Number of subjects: 114
Study 38858743 — intervention group
Group type: COMPARATOR
Intervention: Digital psychological control intervention (B1)
Number of subjects: 114
Study 38858795 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Pressure Support (NPS)
Number of subjects: 24
Study 38858795 — intervention group
Group type: COMPARATOR
Intervention: Standard Pressure Support Ventilation (PSV)
Number of subjects: 24
Study 38858818 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 10 or 20 mg depending on eGFR above or below 60 mL/min/1.73 m2
Number of subjects: 1584
Study 38858818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study 38858818 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 1584
Study 38859627 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless procedure with enamel matrix derivatives (EMD)
Number of subjects: 46
Study 38859627 — intervention group
Group type: COMPARATOR
Intervention: Flapless procedure alone
Number of subjects: 46
Study 38859640 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention targeting hip strengthening (NEMEX-STR)
Number of subjects: 84
Study 38859640 — intervention group
Group type: COMPARATOR
Intervention: Standard community-based rehabilitation (Usual care)
Number of subjects: 84
Study 38859644 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose edoxaban (30 mg)
Number of subjects: 586
Study 38859744 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab treatment
Number of subjects: 139
Study 38859744 — intervention group
Group type: COMPARATOR
Intervention: No CGRP-induced migraine (Control)
Number of subjects: 139
Study 38859822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering methodology applied to caregiver experience profiles
Number of subjects: 0
Study 38859822 — intervention group
Group type: EXPERIMENTAL
Intervention: Support interventions tailored to caregiver experience profiles
Number of subjects: 0
Study 38859883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous odatroltide (0.025 mg/kg)
Number of subjects: 24
Study 38859883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38860025 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC PrEP (two, four, or seven doses per week for 8 weeks)
Number of subjects: 45
Study 38860025 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC PrEP (seven doses per week for 8 weeks)
Number of subjects: 45
Study 38860054 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index, PSQI)
Number of subjects: 499
Study 38860054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EQ-5D score
Number of subjects: 499
Study 38860054 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Cognitive Reserve Questionnaire (CRC) score
Number of subjects: 499
Study 38860057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth noise-canceling headphones
Number of subjects: 29
Study 38860057 — intervention group
Group type: COMPARATOR
Intervention: Control (smartphone at normal speech volume 60 decibels)
Number of subjects: 29
Study 38860154 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 88
Study 38860154 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study 38860389 — intervention group
Group type: EXPERIMENTAL
Intervention: AIH+HIT
Number of subjects: 35
Study 38860389 — intervention group
Group type: COMPARATOR
Intervention: normoxia+HIT
Number of subjects: 35
Study 38860394 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a) ≥150 nmol/L
Number of subjects: 714
Study 38860394 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxidized phospholipid concentrations
Number of subjects: 714
Study 38860394 — intervention group
Group type: COMPARATOR
Intervention: Stage A/B HF
Number of subjects: 714
Study 38860396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 5796
Study 38860396 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 5796
Study 38860554 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal habit recommendations (breakfast and late-evening snack habits)
Number of subjects: 0
Study 38860554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 38860591 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 dose 4 in 6-month- to <5-year-olds
Number of subjects: 0
Study 38860591 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 in 5- to <12-year-olds
Number of subjects: 0
Study 38860591 — intervention group
Group type: COMPARATOR
Intervention: original BNT162b2 dose 3
Number of subjects: 0
Study 38860591 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 dose 4
Number of subjects: 0
Study 38860727 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise therapy (PR)
Number of subjects: 79
Study 38860727 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 79
Study 38860901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (detailed dosage and duration not specified)
Number of subjects: 142
Study 38860901 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 142
Study 38860935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Er:YAG laser (nonablative, Smooth mode, 2,940 nm)
Number of subjects: 20
Study 38860996 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 646
Study 38861137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 187
Study 38861192 — intervention group
Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6
Number of subjects: 89
Study 38861192 — intervention group
Group type: COMPARATOR
Intervention: placebo-mFOLFOX6
Number of subjects: 89
Study 38861286 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 38861286 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (lower starting doses)
Number of subjects: 0
Study 38861294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus chemotherapy
Number of subjects: 0
Study 38861294 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 0
Study 38861294 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38861293 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX-009 with paclitaxel
Number of subjects: 0
Study 38861301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus tiragolumab
Number of subjects: 0
Study 38861301 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab plus bevacizumab
Number of subjects: 0
Study 38861324 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized anemia therapy
Number of subjects: 0
Study 38861324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38861361 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin 90 Y radioembolization
Number of subjects: 30
Study 38861398 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Number of subjects: 1158
Study 38861398 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogramming to the secondary vector
Number of subjects: 1158
Study 38861398 — intervention group
Group type: EXPERIMENTAL
Intervention: System removal and subsequent S-ICD reimplantation
Number of subjects: 1158
Study 38861398 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD system exchange
Number of subjects: 1158
Study 38861659 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavior therapy (bCBT)
Number of subjects: 0
Study 38861659 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 38861659 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 0
Study 38861666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib plus venetoclax (PV)
Number of subjects: 25
Study 38861666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib plus venetoclax and rituximab (PVR)
Number of subjects: 25
Study 38861681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids (HA) fitted for 1 year
Number of subjects: 86
Study 38861707 — intervention group
Group type: EXPERIMENTAL
Intervention: POSSIBLE intervention using the PrEPme app and peer change agent (PCA)
Number of subjects: 69
Study 38861707 — intervention group
Group type: EXPERIMENTAL
Intervention: POSSIBLE intervention
Number of subjects: 69
Study 38861793 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium (shake containing 700 mg Ca/day)
Number of subjects: 14
Study 38861793 — intervention group
Group type: COMPARATOR
Intervention: Low calcium (shake with 6.4 mg Ca/day)
Number of subjects: 14
Study 38861793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups on energy-restricted diets (-500 kcal/d, 800 mg of dietary Ca/d)
Number of subjects: 14
Study 38861871 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus letrozole
Number of subjects: 1186
Study 38861871 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 1186
Study 38861871 — intervention group
Group type: COMPARATOR
Intervention: placebo plus letrozole
Number of subjects: 1186
Study 38861871 — intervention group
Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 1186
Study 38861890 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association (AHA diet)
Number of subjects: 98
Study 38861890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean pattern diet (FLiO diet)
Number of subjects: 98
Study 38861890 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline chemerin, leptin, LECT2, and M65
Number of subjects: 98
Study 38861890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers (leptin, adiponectin, M30, LECT2)
Number of subjects: 98
Study 38861890 — intervention group
Group type: COMPARATOR
Intervention: Control group (forty-five subjects)
Number of subjects: 98